CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NovAccess Global Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NovAccess Global Inc
8584 E. WASHINGTON STREET, NO. 127
Phone: (213) 642-9268p:213 642-9268 CHAGRIN FALLS, OH  44023  United States Ticker: XSNXXSNX
Business Summary
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20249/30/2023YesYes--Yes

Industries
SIC Code Description
3081 Unsupported plastics film and sheet
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board John A.Cassarini 45 3/14/2022 3/14/2022
Chief Executive Officer, Interim Principal Financial Officer, Director Dwain K.Moris - Irvin 55 7/26/2024 10/15/2020
Independent Director Jason M.Anderson 49 3/24/2022 3/24/2022

Business Names
Business Name
StemVax, LLC
SUN RIVER MINING INC
XSNX
XSNXD
XSUNX INC

General Information
Number of Employees: 1 (As of 9/30/2023)
Outstanding Shares: 61,906,932 (As of 10/29/2024)
Shareholders: 354
Stock Exchange: OTC
Federal Tax Id: 841384159
Fax Number: (949) 266-5823


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024